In honor of the 60th anniversary of the UN’s Universal Declaration of Human Rights, Novozymes is focusing on human rights in this new Quarterly Report.
In partnership with the Technical University of Denmark, Novozymes is providing a million-kroner sponsorship that will open up the possibility for the country’s upper- secondary school pupils to really get to grips with biotechnology.
Anyone who has washed or worn white clothes knows that white shirts stop looking white after a few washes and start to turn a shade of gray. Same is the case with striped clothes as they tend to lose their contrast after a few washes and the white and colored stripes start to look dull.
A Novozymes project has been awarded the prestigious European Lipid Technology Award 2008.
To meet the rising demand for biopharmaceutical production, Novozymes has refurbished its current Good Manufacturing Practice (cGMP) facility in Lund, Sweden.
4 million tons of CO2 reduction plus an economic bonus of 2.5% savings on feed are what enzymes can do for the pork industry.
Novozymes has decided to consolidate its current pharma production by transferring the manufacture of LONG®R3-IGF-I* from Adelaide, Australia, to Lund, Sweden.
DSM Nutritional Products and Novozymes restate their commitment to the feed market by renewing their strategic alliance agreement. With the renewal of the agreement, the two companies commit to further strengthening and developing their partnership.
Novozymes’ Project DECREASE (Development of a Commercial-Ready Enzyme Application System for Ethanol) aims to improve performance of Novozymes’ most advanced cellulase system, further decreasing the cost of cellulosic ethanol production.
Novozymes is revolutionizing corporate reporting and launching a reporting universe where issues raised in the annual report are updated, expanded and developed throughout the year. In 2008 Novozymes is again the first company in the Copenhagen Stock Exchange’s OMXC20 blue-chip index to publish its annual report.
Cargill and Novozymes today announced a joint agreement to develop technology enabling the production of acrylic acid via 3-hydroxypropionic acid (3HPA) from renewable raw materials. The project is supported by a $1.5 million matching cooperative agreement from the U.S. Department of Energy.
Novozymes has decided to close its production facility in the Shandong Province, China, by January 7, 2008. As a result of the closure, Novozymes will no longer produce or sell streptococcal based hyaluronic acid but maintain its focus on bacillus based hyaluronic acid.
Sign up for RSS-feeds
We are introducing RSS-feeds as a new easy way of retrieving updates from Novozymes.com
Sign up for RSS-feeds here